Science Corp's Vision Restoring Eye Chip Wins EU Approval

Science Corporation, a brain-computer interface (BCI) developer founded by former Neuralink co-founder Max Hodak, has received European regulatory approval to begin clinical trials for its 'Science Eye' subretinal implant. The device targets patients suffering from severe vision loss due to geographic atrophy.

Unlike Neuralink's cortical arrays, the Science Eye is a thin, flexible optoelectronic prosthesis placed directly onto the retina. It uses a high-resolution micro-LED display combined with gene therapy to stimulate the optic nerve, bypassing damaged photoreceptor cells to transmit visual data to the brain.

Bionic Retinal Prosthesis Ready for Human Trials

The European approval represents a major milestone for Science Corporation as it seeks to demonstrate the safety and efficacy of its neural interface in human trials. The company will begin recruiting participants at clinical sites in France and Germany, aiming to restore basic visual acuity and reading capabilities.

Pioneering RESTorative Neural Interfaces

The neural engineering sector is expanding rapidly, with several firms competing to bring bionic vision solutions to market. As regulatory paths for BCI devices become more standardized, patient access to restorative neural interfaces is expected to increase, offering new treatment options for degenerative visual disorders.